1. At a Glance – Small Pharma, Big Mood Swings
Market Cap: ₹143 Cr
Current Price: ₹67.6
Stock P/E: 12.3
Price to Book: 0.78
ROCE: 15.8%
ROE: 12.1%
Debt: ₹0 Cr
Return (3 months): -21.3%
Alpa Laboratories is that small-cap pharma stock which looks cheap, smells cheap, trades cheap… but then suddenly drops -78% quarterly profit variation and reminds you that cheap things come with emotional baggage. Q3 FY26 revenue stands at ₹29.05 Cr and PAT at ₹1.90 Cr. Sounds fine? Wait till you see the margin drama and that chunky “Other Income” story.
It’s trading below book value. It has zero debt. It shows 49% profit CAGR over 5 years. But also: negative OPM TTM and ₹18.4 Cr of other income baked into earnings.
So the real question is — is this a silent turnaround brewing… or just accounting seasoning?
Let’s open the capsule and read the ingredients.
2. Introduction – The Generic Pharma Underdog
Founded in 1988, Alpa Laboratories manufactures pharmaceutical finished dosage forms. Human drugs. Veterinary drugs. Ethical. Generic. OTC. Basically, if it comes in a tablet, capsule, injection, or ointment form — they probably make some version of it.
WHO-GMP certified. ISO certified. Respectable.
But size? Tiny.
With annual sales of ₹114 Cr (TTM), this is a minnow swimming among whales like:
- Sun Pharmaceutical Industries Ltd
- Divi’s Laboratories Ltd
- Cipla Ltd
- Dr. Reddy’s Laboratories Ltd
These giants print quarterly profits larger than Alpa’s entire annual revenue.
But here’s where it gets interesting:
Small pharma companies sometimes create disproportionate returns when:
- They clean up balance sheets
- Improve working capital
- Or simply stop relying on “other income”
Alpa has already reduced debt to zero. That’s a positive signal.
But then we see:
- High debtor days: 155
- Earnings include ₹18.4 Cr other income
- Poor sales growth (5% CAGR over 5 years)
So is this a value trap… or value opportunity?
Let’s dissect it.
3. Business Model – WTF Do They Even Do?
Imagine a pharmaceutical factory in Indore (interpretation based on company’s known operations), manufacturing:
Capsules: Ampicillin, Cloxacillin, Doxycycline
Tablets: Metformin, Ibuprofen, Losartan
Injections: Amikacin, Diazepam, Vitamin B
Creams: Clotrimazole, Diclofenac
Veterinary boluses with minerals and antibiotics
In simple terms:
They are a contract and branded generics manufacturer.
They:
- Manufacture under own brand
- Manufacture for other companies
- Sell across human & veterinary categories
Revenue breakup FY23:
- 89% manufactured goods
- 2% stock-in-trade
- 9% other income
Now ask yourself:
Why is “Other Income” 9% of revenue for a pharma manufacturer?
Are they in pharma… or in finance?
That’s a pattern we need to track carefully.
They are also:
- Partner (18%) in Seabright Landmark Projects LLP
- Pending merger of Norfolk Mercantile Pvt Ltd before NCLT
So apart from tablets and capsules, there’s a bit of legal paperwork cooking too.
4. Financials Overview – The Quarterly Drama
EPS:
- Jun 2025: ₹5.59
- Sep 2025: ₹0.05
- Dec 2025: ₹0.90
Average = (5.59 + 0.05 + 0.90) / 3 = 2.18
